AbbVie Inc v. Apotex Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: AbbVie Inc. (Delaware) and Allergan Pharmaceuticals International Limited (Ireland)
  • Defendant: Apotex Inc. (Canada)
  • Plaintiff's Counsel: McCarter & English, LLP
• Case Identification: 3:26-cv-11154, D.N.J., 08/28/2026
• Venue Allegations: Venue is alleged to be proper as Defendant Apotex may be sued in any judicial district because it is a foreign corporation. Additionally, Apotex is alleged to conduct substantial business in the District of New Jersey, and the district is a likely destination for the accused generic products.
• Core Dispute: Plaintiffs allege that Defendant's Abbreviated New Drug Application (ANDA) to market a generic version of the migraine prevention drug QULIPTA® (atogepant) constitutes an act of infringement of two patents covering specific methods of treatment.
• Technical Context: The technology involves specific dosing regimens for atogepant, an oral calcitonin gene-related peptide (CGRP) receptor antagonist, used for the preventive treatment of migraine in distinct patient populations.
• Key Procedural History: This is a Hatch-Waxman action initiated under 35 U.S.C. § 271(e)(2) following Apotex's submission of ANDA No. 220979. The complaint states Plaintiffs received a Paragraph IV certification notice from Apotex regarding the '897 patent but had not yet received one for the '341 patent. The parties are involved in prior litigation concerning other patents related to the same drug.

Case Timeline

Date	Event
2021-09-27	Priority Date for '897 and '341 Patents
2021-09-28	FDA Approved Plaintiffs' QULIPTA® (atogepant) NDA
2025-12-23	Plaintiffs filed "First Suit" against Apotex
2026-05-12	U.S. Patent No. 12,622,897 Issued
2026-06-23	U.S. Patent No. 12,661,341 Issued
2026-07-15	Apotex sent Second Notice Letter regarding the '897 patent
2026-08-28	Complaint Filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,622,897 - "Methods of Treating Migraine," Issued 05/12/2026

The Invention Explained

• Problem Addressed: The patent's background section identifies a need for "targeted methodologies and dosing regimens to use oral CGRP treatments to prophylactically treat migraines" '897 Patent, col. 1:42-45 This addresses the challenge of safely and effectively administering such drugs to specific patient populations who may have other medical conditions or be taking other medications.
• The Patented Solution: The invention provides specific methods for the preventive treatment of migraine with atogepant, a CGRP receptor antagonist, by tailoring the dosage based on the patient's specific circumstances '897 Patent, abstract The patent describes distinct dosing regimens for patients who are concurrently taking certain other drugs (e.g., CYP3A4 inhibitors or inducers) or who have specific medical conditions like renal impairment, thereby managing potential drug-drug interactions and safety risks '897 Patent, col. 4:18-54 '897 Patent, col. 8:12-62
• Technical Importance: This approach enables the use of atogepant in complex patient cases by providing clinically tested, specific dosing instructions that account for factors known to alter drug metabolism and exposure, thereby broadening the drug's applicability.

Key Claims at a Glance

• The complaint asserts infringement of one or more unspecified claims of the '897 patent Compl. ¶62 Independent claims 1 and 6 are representative of the patent's scope.
• Independent Claim 1 includes the following essential elements:
  • A method for the preventive treatment of migraine in a patient.
  • The patient is undergoing concurrent treatment with a strong CYP3A4 inhibitor.
  • The method comprises administering atogepant 10 mg once daily.
• Independent Claim 6 includes the following essential elements:
  • A method for the preventive treatment of migraine in a patient.
  • The patient has severe renal impairment or end-stage renal disease (CLcr<30 mL/min).
  • The method comprises administering 10 mg atogepant once daily.

U.S. Patent No. 12,661,341 - "Methods of Treating Migraine," Issued 06/23/2026

The Invention Explained

• Problem Addressed: As with the '897 patent, the background section identifies a need for "targeted methodologies and dosing regimens" for oral CGRP antagonists used in migraine prevention '341 Patent, col. 1:42-45
• The Patented Solution: The invention provides a method for preventively treating migraine with atogepant specifically in patients who have "mild or moderate hepatic impairment" '341 Patent, abstract The patent claims that administering a dose of 10 mg, 30 mg, or 60 mg once daily is safe and effective for this patient subpopulation, thereby defining a specific treatment protocol for individuals with compromised liver function '341 Patent, col. 9:1-16
• Technical Importance: By establishing a safe and effective dosing range for patients with mild to moderate liver impairment, the invention allows a vulnerable patient population to access the therapeutic benefits of atogepant.

Key Claims at a Glance

• The complaint asserts infringement of one or more unspecified claims of the '341 patent Compl. ¶91 The patent contains one independent claim.
• Independent Claim 1 includes the following essential elements:
  • A method for the preventive treatment of migraine in a patient.
  • The patient has mild or moderate hepatic impairment.
  • The method comprises orally administering a dose selected from the group consisting of 10 mg, 30 mg, and 60 mg atogepant once daily to the patient.

III. The Accused Instrumentality

Product Identification

The accused instrumentalities are Apotex's proposed generic atogepant oral tablets in 10 mg, 30 mg, and 60 mg dosage forms, for which Apotex filed ANDA No. 220979 seeking FDA approval Compl. ¶1 Compl. ¶43

Functionality and Market Context

• The complaint alleges that Apotex's generic products are intended for the preventive treatment of migraine in adults, functioning as a CGRP receptor antagonist Compl. ¶30
• As an ANDA product, Apotex's generic must be bioequivalent to the reference listed drug, QULIPTA® Tablets Compl. ¶52 Crucially, the complaint alleges that the proposed labeling for the generic product must recommend the same conditions of use as those previously approved for QULIPTA®, which Plaintiffs allege include the patented methods of treatment Compl. ¶53
• The complaint positions QULIPTA® as a significant product, noting it is one of only two orally available CGRP receptor antagonists for migraine prevention and the only one with specific dosage recommendations for concomitant use with OATP inhibitors Compl. ¶33

IV. Analysis of Infringement Allegations

The complaint alleges infringement under 35 U.S.C. § 271(e)(2)(A), where the filing of an ANDA for a patented drug is a statutory act of infringement Compl. ¶61 The substantive theory is that Apotex will induce infringement under 35 U.S.C. § 271(b) by marketing the generic product with a label that instructs medical professionals and patients to use it in accordance with the patented methods Compl. ¶62 Compl. ¶65 No probative visual evidence provided in complaint.

'897 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for the preventive treatment of migraine in a patient...	Apotex's ANDA seeks approval to market a generic version of atogepant for the preventive treatment of migraine.	¶43	col. 4:18-20
...undergoing concurrent treatment with a strong CYP3A4 inhibitor,	The proposed product label is expected to contain the same indications as the QULIPTA® label, which includes instructions for use in patients taking concomitant medications, such as strong CYP3A4 inhibitors.	¶32; ¶53; ¶65	col. 4:18-23
the method comprising administering atogepant 10 mg once daily.	Apotex seeks approval for a 10 mg dosage form, and its label is expected to instruct the administration of this dose to patients taking strong CYP3A4 inhibitors, thereby directing users to perform the patented method.	¶43; ¶65	col. 4:40-44

'341 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A method for the preventive treatment of migraine in a patient...	Apotex's ANDA seeks approval to market a generic version of atogepant for the preventive treatment of migraine.	¶43	col. 9:1-2
...having mild or moderate hepatic impairment,	The proposed product label is expected to contain the same indications as the QULIPTA® label, which includes instructions for use in patients with mild or moderate hepatic impairment.	¶32; ¶53; ¶94	col. 9:1-3
the method comprising orally administering a dose selected from the group consisting of 10 mg, 30 mg, and 60 mg atogepant once daily to the patient.	Apotex seeks approval for 10 mg, 30 mg, and 60 mg dosage forms, and its label is expected to instruct administration of these dosages in patients with mild or moderate hepatic impairment.	¶43; ¶94	col. 9:12-16

• Identified Points of Contention:
  • Infringement Scope: The primary dispute will likely center on induced infringement. A key question is whether Apotex's proposed label will contain the specific instructions that form the basis of the patented methods. Apotex may argue it intends to market its product with a "skinny label" that carves out the patented methods of use, which would raise the question of whether such a carve-out is legally and commercially sufficient to avoid infringement.
  • Validity: Apotex has asserted that the claims of the '897 patent are invalid and/or unenforceable Compl. ¶59 A central question for the court will be whether the claimed dosing regimens represent a non-obvious inventive step over the prior art. Apotex may argue that dose adjustments for specific patient populations (e.g., those with renal/hepatic impairment or on interacting drugs) are routine and predictable steps in clinical drug development.

V. Key Claim Terms for Construction

'897 Patent

• The Term: "strong CYP3A4 inhibitor" (from Claim 1)
• Context and Importance: The definition of this term is critical for determining the exact patient population covered by Claim 1. The dispute will likely focus on whether this term is limited to specific examples or extends to any drug causing a certain degree of metabolic inhibition. Practitioners may focus on this term because its breadth directly impacts the number of potential direct infringers (patients) and thus the scope of Apotex's alleged inducement.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The specification discusses a hierarchy of weak, moderate, and strong inhibitors, suggesting "strong" is a functional category defined by its effect on atogepant exposure, not just a list of compounds. The patent notes that co-administration with itraconazole, a strong inhibitor, resulted in a "significant increase in exposure" '897 Patent, col. 4:18-24 This may support an interpretation based on clinical effect.
  • Evidence for a Narrower Interpretation: The specification provides a specific, limited list of examples: "ketoconazole, itraconazole, clarithromycin" '897 Patent, col. 4:37-39 A party could argue the term should be construed as being limited to this class of compounds or those with a virtually identical mechanism and potency of inhibition.

'341 Patent

• The Term: "mild or moderate hepatic impairment" (from Claim 1)
• Context and Importance: This term defines the patient population for the asserted claims of the '341 patent. Its construction is key to defining the boundaries of infringement.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The term could be argued to cover any patient a clinician diagnoses with mild or moderate hepatic impairment based on their overall clinical judgment, even without formal scoring. This would broaden the pool of potential infringers.
  • Evidence for a Narrower Interpretation: The specification provides an explicit definition tied to a specific clinical scale: "The term 'hepatic impairment' refers to scoring based on the Child-Pugh Score of A, B, and C. In embodiments, mild hepatic impairment refers to Child-Pugh Class A; moderate hepatic impairment refers to Child-Pugh Class B" '341 Patent, col. 9:4-9 This language provides strong support for a narrow construction limited to patients formally classified under this scoring system.

VI. Other Allegations

• Indirect Infringement: The complaint's primary infringement theory is induced infringement under 35 U.S.C. § 271(b). It alleges Apotex knows of the patents-in-suit and intends for healthcare providers and patients to infringe by following the instructions on the proposed generic drug label, which will mirror the label for QULIPTA® and direct the patented methods of use (Compl. ¶63; Compl. ¶64; Compl. ¶65; Compl. ¶66).
• Willful Infringement: The complaint does not explicitly allege "willful infringement." However, it requests a declaration that the case is "exceptional" and seeks an award of attorney fees under 35 U.S.C. § 285 Compl., Prayer G This is often predicated on conduct equivalent to willfulness. The alleged basis is Apotex's pre-suit knowledge of the '897 patent via a notice letter and its decision to proceed with its ANDA filing, and knowledge of the '341 patent via the filing of the complaint itself Compl. ¶64 Compl. ¶87

VII. Analyst's Conclusion: Key Questions for the Case

1. Labeling and Induced Infringement: A core issue will be one of infringement by labeling. Can Apotex successfully use a "skinny label" to carve out the patented methods of use, or will the instructions and indications on its FDA-approved generic label inevitably encourage or instruct physicians to prescribe atogepant according to the specific, patented dosing regimens for patients with interacting medications or organ impairment?
2. Obviousness of Dosing Regimens: The central validity question will be one of predictability in drug development. Does tailoring a drug's dosage for specific subpopulations-such as patients with hepatic impairment (per the '341 patent) or those taking known metabolic inhibitors (per the '897 patent)-constitute a non-obvious invention, or will the court find it to be a routine and obvious step for a person of ordinary skill in the art of pharmacology?
3. Jurisdictional Ripeness: For the '341 patent, a threshold question is justiciability. As Plaintiffs filed suit before receiving a formal Paragraph IV notice for this patent, the court must first decide if Apotex's ANDA submission for a bioequivalent drug creates a sufficiently concrete and immediate controversy to support a declaratory judgment action for infringement.